Fumiquinazolines F and G from the Fungus Penicillium thymicola Demonstrates Anticancer Efficacy Against Triple-Negative Breast Cancer MDA-MB-231 Cells by Inhibiting Epithelial–Mesenchymal Transition
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157582 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Gleb K Rystsov und 7 weiteren Autor:innen. Beteiligte Einrichtung: G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Pushchino Scientific Center for Biological Research of the Russian Academy …. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Penicillium, Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The secondary metabolites of the fungus Penicillium thymicola, fumiquinazolines F and G, have antibacterial and antifungal characteristics; however, their potential anti-tumor action against human cancer cells remains unknown. The goal of our study was to determine the biological efficacy of fumiquinazolines F and G on breast and prostate cancer cells. Cancer cell proliferation and migration were monitored in real time using xCELLigence technology and flow cytometry. Alterations in mRNA and protein expression were assessed by RT-qPCR, ELISA, and Western blotting. Our data indicate that fumiquinazolines F and G are more effective in inhibiting breast cancer cell proliferation than prostate cancer cells. Fumiquinazoline F is active against both hormone-dependent epithelial MCF-7 (IC50 48 μM) and hormone-resistant triple-negative mesenchymal MDA-MB-231 breast cancer cells (IC50 54.1 μM). The metabolite has low cytotoxicity but slows cell cycle progression. In fumiquinazoline F-treated MDA-MB-231 cells, the levels of proteins implicated in epithelial–mesenchymal transition (EMT) (such as E-cadherin, vimentin, and CD44) fluctuate, resulting in a decrease in cell migratory rate and adhesion to a hyaluronic acid-coated substrate. Thus, fumiquinazolines F and G exhibit anticancer activity by inhibiting EMT, cell proliferation, and migration, hence reverting malignant cells to a less pathogenic phenotype. The compound’s multi-target anticancer profile underscores its potential for further exploration of novel EMT-regulating pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences, Pushchino 142290, Russia.
- All-Russian Institute of Plant Protection, Pushkin, Saint-Petersburg 196608, Russia.
ORCID-Profile: Gleb K Rystsov, Tatiana V Antipova, Zhanna V Renfeld, Mikhail B Vainshtein, Igor E Granovsky
Zitieren
APA
Rystsov, G. K., Antipova, T. V., Renfeld, Z. V., Pilguy, L. S., Shlyapnikov, M. G., Vainshtein, M. B., Granovsky, I. E., & Zemskova, M. Y. (2025). Fumiquinazolines F and G from the Fungus Penicillium thymicola Demonstrates Anticancer Efficacy Against Triple-Negative Breast Cancer MDA-MB-231 Cells by Inhibiting Epithelial–Mesenchymal Transition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157582
Vancouver
Rystsov GK, Antipova TV, Renfeld ZV, Pilguy LS, Shlyapnikov MG, Vainshtein MB, et al. Fumiquinazolines F and G from the Fungus Penicillium thymicola Demonstrates Anticancer Efficacy Against Triple-Negative Breast Cancer MDA-MB-231 Cells by Inhibiting Epithelial–Mesenchymal Transition. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157582
BibTeX
@article{Rystsov2025,
author = {Rystsov, Gleb K and Antipova, Tatiana V and Renfeld, Zhanna V and Pilguy, Lidiya S and Shlyapnikov, Michael G and Vainshtein, Mikhail B and Granovsky, Igor E and Zemskova, Marina Y},
title = {Fumiquinazolines F and G from the Fungus Penicillium thymicola Demonstrates Anticancer Efficacy Against Triple-Negative Breast Cancer MDA-MB-231 Cells by Inhibiting Epithelial–Mesenchymal Transition},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157582}
}
EUVIMED